Specialty Oncology
-
Featured
Biomarkers of T Cell Exhaustion in Checkpoint Inhibitor Therapy
Could altering the balance between two CD8+ T cell states enhance immunotherapies? Research from the Massachusetts General Hospital Cancer Center seeks to find the answer.
-
CRISPR Base Editors Can Induce Wide-Ranging Off-Target Edits in RNA
The DNA deaminases contained in CRISPR-Cas cytosine and adenine base editors can induce extensive edits in RNA—and researchers at the Massachusetts General Hospital Cancer Center have engineered improved editors that substantially reduce these unwanted effects.
-
Inactivating Mutation in the Histone Deacetylase SIRT6 Discovered to Be a Cause of Fetal Demise
Showing for the first time that a chromatin regulator can underlie perinatal lethality, Massachusetts General Hospital Cancer Center researchers have identified a loss-of-function mutation in SIRT6 that was associated with four cases of severe congenital anomalies and late fetal death.
-
Innovative Zebrafish Model Allows Visualization of Response to Cancer Drugs Over Time at Single-Cell Level and Leads to New Clinical Trial
Zebrafish generated by Massachusetts General Hospital Cancer Center and Massachusetts General Hospital's Department of Pathology researchers remain immunodeficient into adulthood and are transparent, allowing direct visualization of individual cells and their response to cancer therapy over time.
-
Subset of Cancer Patients with Checkpoint Inhibitor–Associated Enterocolitis Respond to Budesonide
Checkpoint inhibitor–related microscopic colitis, a subset of checkpoint inhibitor–related enterocolitis, often responds to first-line budesonide, allowing patients to remain on immunotherapy.
-
Finding New Approaches to Treat Desmoid Tumor Patients
Surgery for desmoid tumors is only about 50% effective. Multidisciplinary care may be more effective for helping patients find relief.
Oncology contributors
-
Andrew T. Chan, MD, MPH
Professor of Medicine, Harvard Medical School, Director for Cancer Epidemiology, Mass General Cancer Center, Chief, Clinical and Translational Epidemiology Unit, Department of Medicine
Recent Article
COVID-19 Symptom App to Study Disease Onset and Progression
-
David M. Langenau, PhD
Associate Professor of Pathology, Harvard Medical School, Associate Chair for Research, Department of Pathology, Massachusetts General Hospital
-
J. Keith Joung, MD, PhD
Professor of Pathology, Harvard Medical School, Center for Cancer Research, Desmond and Ann Heathwood MGH Research Scholar
Recent Article
CRISPR Base Editors Can Induce Wide-Ranging Off-Target Edits in RNA
-
Joseph H. Schwab, MD
Chief, Orthopaedic Spine Surgery, Director, Spine Oncology & Co-Director, Stephen L. Harris Chordoma Center, Associate Professor of Orthopedic Surgery, Harvard Medical School
Recent Article
Minor Complications Associated with Increased Mortality Risk After Surgery for Metastases in Long Bones
-
Keith T. Flaherty, MD
Director of Clinical Research, Mass General Cancer Center, Professor of Medicine, Harvard Medical School
Recent Article
Medical Grand Rounds: Advancing New Therapies for COVID-19: Antiviral, Immunomodulation and Beyond
-
Marcela G. del Carmen, MD
Chief Medical Officer, Massachusetts General Physicians Organization, Gynecologic Oncologist, Center for Gynecologic Oncology
Recent Article
Editorial: It's Time to Study "Hospital at Home" After Surgery
-
Marcela V. Maus, MD, PhD
Director, Cellular Immunotherapy Program, Mass General Cancer Center, Assistant Professor of Medicine, Harvard Medical School
Recent Article
New Approach to CAR T-Cell Therapy for Glioblastoma Aims to Circumvent Antigen Escape -
Nir Hacohen, PhD
Director, MGH Center for Cancer Immunology
Center for Cancer Research , Professor of Medicine, Harvard Medical School, Senior Member, Broad InstituteRecent Article
Biomarkers of T Cell Exhaustion in Checkpoint Inhibitor Therapy
-
Raul Mostoslavsky, MD, PhD
Laurel Schwartz Professor of Medicine in the Field of Oncology, Mass General Cancer Center, Center for Cancer Research
Recent Article
Inactivating Mutation in the Histone Deacetylase SIRT6 Discovered to Be a Cause of Fetal Demise
-
Whitfield B. Growdon, MD
Center for Gynecologic Oncology
Recent Article
Developing Precision Therapies for Ovarian Cancer
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology
Recent Article
Endonasal Surgery Using High-Speed Drill Puts Health Care Team at Risk of COVID-19
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
